Last updated on September 2017

Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies


Brief description of study

The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with TGR-1202, with or without ibrutinib or bendamustine, in patients with advanced hematologic malignancies

Clinical Study Identifier: NCT02006485

Contact Investigators or Research Sites near you

Start Over

TG Therapeutics Clinical Support Team

TG Therapeutics Investigational Trial Site
Huntsville, AL United States
  Connect »

TG Therapeutics Clinical Support Team

TG Therapeutics Investigational Trial Site
Jonesboro, AR United States
  Connect »

TG Therapeutics Clinical Support Team

TG Therapeutics Investigational Trial Site
Duarte, CA United States
  Connect »

TG Therapeutics Clinical Support Team

TG Therapeutics Investigational Trial Site
Atlanta, GA United States
  Connect »

TG Therapeutics Clinical Support Team

TG Therapeutics Investigational Trial Site
Omaha, NE United States
  Connect »

Nathan Fowler, MD

MD Anderson Cancer Center
Houston, TX United States
  Connect »